Logo
Login
$AMPH
$25.57 +$0.10 (0.39%) Close

Company Executives

$AMPH Management Team

Mr. Dan Dischner

Vice President - Corporate Communications

Age -
Compensation -
Sex Male

Dr. Ziping Luo

Chairman of the Board

Chief Operating Officer

Chief Scientist

Age 75
Compensation $3.799M USD
Sex Female

Dr. Yongfeng Zhang

President

Chief Executive Officer

Chief Scientific Officer

Director

Age 78
Compensation $7.735M USD
Sex Male

Mr. Jacob Liawatidewi

Executive Vice President of Sales and Marketing

Corporate Administration Center

President of Amphastar France Pharmaceuticals

S.A.S

Company Secretary

Director

Age 51
Compensation $1.822M USD
Sex Male

Mr. Rong Zhou

Senior Executive Vice President of Production Center

Executive Vice President of Scientific Affairs

President of Amphastar Nanjing Pharmaceuticals

Co.

Ltd.

Age 66
Compensation $2.128M USD
Sex Male

Mr. William Peters

Chief Financial Officer

Executive Vice President - Finance

Treasurer

President of International Medication Systems Limited

Director

Age 57
Compensation $2.911M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 13, 2026
Directors
11
serving now
Independent
0 of 1
stated in the proxy; 10 not stated
Average tenure
11.9 years
from year joined
CEO also chairs the board
No
Mary Z. Luo
Director Age On board Independent Committees Other public boards 2025 pay Source
David Gaugh
Not stated 2025
1 year
 Not stated
Compensation Committee
None stated $284,727
William J. Peters
Executive officer
 Not stated 2022
4 years
 Not stated None stated None stated Not stated
Jacob Liawatidewi
Executive officer
 Not stated 2022
4 years
 Not stated None stated None stated Not stated
Mary Z. Luo
Board chair, Executive officer
 Not stated Not stated Not independent None stated None stated Not stated
Howard Lee
Not stated 2007
19 years
 Not stated None stated None stated $333,500
Michael A. Zasloff
Not stated 2005
21 years
 Not stated None stated None stated $331,000
Gayle Deflin
Not stated 2021
5 years
 Not stated None stated None stated $340,000
Jack Yongfeng Zhang
CEO, Executive officer
 Not stated Not stated Not stated None stated None stated Paid as CEO
Richard Prins
Lead independent director
 Not stated 2002
24 years
 Not stated None stated IGC Pharma, Inc. $377,500
Diane G. Gerst
Not stated 2019
7 years
 Not stated None stated None stated $327,750
Floyd F. Petersen Leaving at the meeting
Not stated 2004
22 years
 Not stated None stated None stated $325,000

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

6 disclosed in the proxy filed Apr 13, 2026
Dr. Jack Zhang and Dr. Mary Luo
Dr. Jack Zhang is our Chief Executive Officer, President, and Director; Dr. Mary Luo is our Chairman, Chief Operating Officer, and Director; with certain family members, they beneficially own a majority of the equity interest in Hanxin
Amount not stated

ANP entered into contract manufacturing agreements under which Hanxin will engage ANP to manufacture products on a cost-plus basis; Company recognized revenue from manufacturing services

With Nanjing Hanxin Pharmaceutical Technology Co., Ltd. Open in proxy
Dr. Jack Zhang and Dr. Mary Luo
Dr. Jack Zhang is our Chief Executive Officer, President, and Director; Dr. Mary Luo is our Chairman, Chief Operating Officer, and Director; with certain family members, they beneficially own a majority of the equity interest in Hanxin
Amount not stated

Contract research agreements under which Hanxin develops research cell banks for the Company; Company paid Hanxin under the agreement and amendment

With Nanjing Hanxin Pharmaceutical Technology Co., Ltd. Open in proxy
Dr. Jack Zhang and Dr. Mary Luo
Dr. Jack Zhang is our Chief Executive Officer, President, and Director; Dr. Mary Luo is our Chairman, Chief Operating Officer, and Director; with certain family members, they beneficially own a majority of the equity interest in Hanxin
$2 million

License agreement under which Hanxin grants the Company an exclusive license to certain intellectual property for corticotropin compound products; Company made an upfront payment to Hanxin

With Nanjing Hanxin Pharmaceutical Technology Co., Ltd. Open in proxy
Henry Zhang (Haoning Zhang)
son of Dr. Jack Zhang, our Chief Executive Officer, President, and Director; beneficially owns a majority of the equity interest in Letop
Amount not stated

Supply agreement under which Letop manufactures and delivers chemical intermediates for ANP on a cost-plus basis; ANP paid Letop under the original agreement

With Nanjing Letop Biotechnology Co., Ltd. Open in proxy
Hanxin
related party; Hong Kong Genreach Limited is a wholly owned subsidiary of Hanxin
Amount not stated

Exclusive distribution agreement for Primatene MIST in Greater China region; Company recognized no revenue from it in fiscal year 2025

With Hong Kong Genreach Limited Open in proxy
Hanxin
related party; Nanjing Chengong Pharmaceutical Co., Limited is a wholly-owned subsidiary of Hanxin
Amount not stated
fiscal year 2025

Exclusive distribution agreement for BAQSIMI in Greater China region; Company recognized no revenue from it in fiscal year 2025

With Nanjing Chengong Pharmaceutical Co., Limited Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans